Published in Cancer on March 15, 2007
Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol (2010) 1.61
Adjuvant colon cancer chemotherapy: Is there an Indian standard of care? South Asian J Cancer (2013) 0.90
Cost-effectiveness of adjuvant FOLFOX and 5FU/LV chemotherapy for patients with stage II colon cancer. Med Decis Making (2013) 0.84
Cost-effectiveness of oxaliplatin in the adjuvant treatment of colon cancer in Canada. Curr Oncol (2010) 0.83
Cost-effectiveness analysis of colon cancer treatments from MOSIAC and No. 16968 trials. World J Gastroenterol (2014) 0.81
Cost-effectiveness of adjuvant chemotherapy with uracil-tegafur for curatively resected stage III rectal cancer. Br J Cancer (2008) 0.79
Extrapolating Survival from Randomized Trials Using External Data: A Review of Methods. Med Decis Making (2016) 0.79
Cost-effectiveness of adjuvant chemotherapy for curatively resected gastric cancer with S-1. BMC Cancer (2013) 0.78
Comparative economics of a 12-gene assay for predicting risk of recurrence in stage II colon cancer. Pharmacoeconomics (2014) 0.76
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med (2004) 18.93
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med (2010) 15.71
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol (2009) 9.24
Expanded screening for HIV in the United States--an analysis of cost-effectiveness. N Engl J Med (2005) 8.49
Long-term persistence in use of statin therapy in elderly patients. JAMA (2002) 7.19
The survival benefits of AIDS treatment in the United States. J Infect Dis (2006) 7.08
The lifetime cost of current human immunodeficiency virus care in the United States. Med Care (2006) 5.87
Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire. N Engl J Med (2006) 5.62
Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med (2006) 5.53
Does preventive care save money? Health economics and the presidential candidates. N Engl J Med (2008) 4.78
Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med (2013) 4.43
When to start antiretroviral therapy in resource-limited settings. Ann Intern Med (2009) 4.31
Medicare and cost-effectiveness analysis. N Engl J Med (2005) 4.20
Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet (2006) 3.60
Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. N Engl J Med (2014) 3.57
Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis (2009) 3.30
Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA (2003) 3.25
Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst (2004) 3.11
Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol (2013) 3.11
Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med (2013) 3.10
Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol (2002) 3.09
Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis (2008) 2.96
Cost-effectiveness of computed tomography screening for lung cancer in the United States. J Thorac Oncol (2011) 2.83
HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol (2004) 2.78
Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med (2005) 2.60
Do health-care decision makers find economic evaluations useful? The findings of focus group research in UK health authorities. Value Health (2002) 2.56
Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med (2003) 2.48
Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis (2005) 2.47
Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis. Med Decis Making (2007) 2.46
Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis. AIDS (2005) 2.39
Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study. Radiology (2008) 2.37
Cost-effectiveness of treating multidrug-resistant tuberculosis. PLoS Med (2006) 2.28
Education in pharmacoeconomics: an international multidisciplinary view. Pharmacoeconomics (2004) 2.25
A DNA methylation fingerprint of 1628 human samples. Genome Res (2011) 2.16
Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Côte d'Ivoire appraisal. PLoS Med (2009) 2.13
The global cost of nonoptimal blood pressure. J Hypertens (2009) 2.00
Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. Med Decis Making (2002) 1.94
The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med (2015) 1.89
Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. Med Decis Making (2012) 1.81
Cost-effectiveness analysis of hypertension guidelines in South Africa: absolute risk versus blood pressure level. Circulation (2005) 1.80
Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making (2002) 1.78
Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--6. Value Health (2012) 1.76
Cost-effectiveness of HIV testing and treatment in the United States. Clin Infect Dis (2007) 1.70
Are Key Principles for improved health technology assessment supported and used by health technology assessment organizations? Int J Technol Assess Health Care (2010) 1.70
Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients. Am J Manag Care (2004) 1.69
Legislating against use of cost-effectiveness information. N Engl J Med (2010) 1.68
The cost effectiveness of gonorrhea screening in urban emergency departments. Sex Transm Dis (2005) 1.64
The lifetime medical cost savings from preventing HIV in the United States. Med Care (2015) 1.61
Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness. J Acquir Immune Defic Syndr (2010) 1.57
Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial. Clin Infect Dis (2007) 1.57
Routine human immunodeficiency virus testing: an economic evaluation of current guidelines. Am J Med (2005) 1.56
Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age. AIDS (2015) 1.49
Ten-year survival and cost following breast cancer recurrence: estimates from SEER-medicare data. Value Health (2008) 1.48
Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res (2006) 1.45
Outcomes and costs of acute treatment of traumatic brain injury. J Trauma (2002) 1.44
The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with men. Clin Infect Dis (2007) 1.43
Cost-effectiveness of posaconazole versus fluconazole for prevention of invasive fungal infections in U.S. patients with graft-versus-host disease. Am J Health Syst Pharm (2012) 1.41
Uncertainty and patient heterogeneity in medical decision models. Med Decis Making (2010) 1.38
Cost-effectiveness of coronary MDCT in the triage of patients with acute chest pain. AJR Am J Roentgenol (2008) 1.37
Comparative effectiveness evidence from the spine patient outcomes research trial: surgical versus nonoperative care for spinal stenosis, degenerative spondylolisthesis, and intervertebral disc herniation. Spine (Phila Pa 1976) (2011) 1.36
Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy. AIDS (2007) 1.34
Clinical outcomes and cost-effectiveness of coronary computed tomography angiography in the evaluation of patients with chest pain. J Am Coll Cardiol (2009) 1.34
HIV drug resistance surveillance for prioritizing treatment in resource-limited settings. AIDS (2007) 1.30
Economic model of a birth cohort screening program for hepatitis C virus. Hepatology (2012) 1.28
Optimal allocation of testing dollars: the example of HIV counseling, testing, and referral. Med Decis Making (2005) 1.28
Empirically calibrated model of hepatitis C virus infection in the United States. Am J Epidemiol (2002) 1.26
Adopting helical CT screening for lung cancer: potential health consequences during a 15-year period. Cancer (2008) 1.26
How much are Americans willing to pay for a quality-adjusted life year? Med Care (2008) 1.26
Economic burden of childhood autism spectrum disorders. Pediatrics (2014) 1.26
Health-care decision-making processes in Latin America: problems and prospects for the use of economic evaluation. Int J Technol Assess Health Care (2005) 1.25
Comparative effectiveness: asking the right questions, choosing the right method. Health Aff (Millwood) (2005) 1.25
Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine (2010) 1.23
Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults. Arch Intern Med (2002) 1.21
Outcome of second-line chemotherapy for biliary tract cancer. Eur J Cancer (2012) 1.21
Collection of health-economic data alongside clinical trials: is there a future for piggyback evaluations? Value Health (2005) 1.18
Population-level changes in folate intake by age, gender, and race/ethnicity after folic acid fortification. Am J Public Health (2006) 1.17
Lifestyle and quality of life in colorectal cancer survivors. Qual Life Res (2011) 1.17
Identifying key parameters in cost-effectiveness analysis using value of information: a comparison of methods. Health Econ (2006) 1.14
When does quality-adjusting life-years matter in cost-effectiveness analysis? Health Econ (2004) 1.14
Estimation of mortality rates for disease simulation models using Bayesian evidence synthesis. Med Decis Making (2006) 1.14
Projected cost-effectiveness of smoking cessation interventions in patients hospitalized with myocardial infarction. Arch Intern Med (2011) 1.14
Treatment for primary HIV infection: projecting outcomes of immediate, interrupted, or delayed therapy. J Acquir Immune Defic Syndr (2002) 1.13
Breast cancer screening in BRCA1 mutation carriers: effectiveness of MR imaging--Markov Monte Carlo decision analysis. Radiology (2008) 1.13
Annual financial impact of well-differentiated thyroid cancer care in the United States. Cancer (2014) 1.13
Measuring the costs of outreach motivational interviewing for smoking cessation and relapse prevention among low-income pregnant women. BMC Pregnancy Childbirth (2009) 1.12
Conducting economic evaluations alongside multinational clinical trials: toward a research consensus. Am Heart J (2005) 1.12
A comparative assessment of non-laboratory-based versus commonly used laboratory-based cardiovascular disease risk scores in the NHANES III population. PLoS One (2011) 1.11
Monitoring of antiretroviral therapy in low-resource settings. Lancet (2008) 1.11
Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines. Arch Intern Med (2002) 1.11
Cost-effectiveness of motivational interviewing for smoking cessation and relapse prevention among low-income pregnant women: a randomized controlled trial. Value Health (2007) 1.09
Antiretroviral drugs for preventing mother-to-child transmission of HIV in sub-Saharan Africa: balancing efficacy and infant toxicity. AIDS (2008) 1.09
Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer. Value Health (2007) 1.06
Public funding of new cancer drugs: Is NICE getting nastier? Eur J Cancer (2009) 1.05
Chapter 9: The MGH-HMS lung cancer policy model: tobacco control versus screening. Risk Anal (2012) 1.05
Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy. Antivir Ther (2002) 1.04
Analysis sans frontières: can we ever make economic evaluations generalisable across jurisdictions? Pharmacoeconomics (2006) 1.04
Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial. AIDS (2012) 1.03
Using QALYs in cancer: a review of the methodological limitations. Pharmacoeconomics (2011) 1.03
Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. Value Health (2004) 1.02